SeraCare Life Sciences and Dr. Jack Wands Spark Advancements in Oncology Diagnostics - - ABC13

SeraCare Life Sciences and Dr. Jack Wands Spark Advancements in Oncology Diagnostics

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE SeraCare Life Sciences, Inc.

MILFORD, Mass., Feb. 11, 2014 /PRNewswire/ -- SeraCare Life Sciences, a provider of high quality biological materials and reagents that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today introduced Dr. Jack Wands as the founding member of the SeraCare Science Advisory Board. This group will bring together thought leaders in emerging technologies and applications such as NexGen sequencing, clinical oncology and autoimmune disease to foster collaboration and innovation.

"We are excited to welcome Dr. Wands as the first member of the SeraCare Science Advisory Board," said Russell Garlick, Ph.D., Chief Scientific Officer at SeraCare. "Dr. Wands is an internationally renowned physician scientist and we share a vision for harnessing the power of precision medicine to advance oncology diagnostics. Each day brings new innovation in our industry, making it more important than ever that we join forces with the leading research minds." 

"SeraCare plays a critical role in the discovery of new diagnostic tools and their transformation into commercial products that improve patients' lives," said Dr. Jack Wands, Professor of Medical Science at Brown Medical School. "It is deeply rewarding to me to join the Science Advisory Board so I can not only share insights with other researchers, but also see these concepts brought to life in a way that positively impacts so many people."

Dr. Wands is the Jeffrey and Kimberly Greenberg-Artemis and Martha Joukowsky Professor in Gastroenterology, and Professor of Medical Science, Brown Medical School. He founded and developed the Rhode Island Hospital/Brown University Liver Research Center. His research efforts involve the role of hepatitis B and C infection in the pathogenesis of hepatocellular carcinoma at the molecular level. Dr. Wands received his M.D. with High Honors from the University Of Washington School Of Medicine, was Chief Resident in Medicine at Johns Hopkins Bayview Medical Center and was a Clinical and Research Fellow at Massachusetts General Hospital.

About SeraCare Life Sciences, Inc.
SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers, and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, KPL antibodies and immunoassay reagents, SeraCon processed plasma, specialty human blood products, and Complete BioCollections materials. SeraCare helps bridge the gap between today's diagnostic solutions and tomorrow's emerging technologies.

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at

Company Contact:

Marsha Ann Marsh

Agency Contact:

Shannon Meirzon

SeraCare Life Sciences, Inc.

Pyxis Communications

508.244.6400 ext. 6106


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WSET. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.